Allianz Asset Management GmbH Purchases New Stake in Emergent Biosolutions Inc. $EBS

Allianz Asset Management GmbH purchased a new stake in Emergent Biosolutions Inc. (NYSE:EBS) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 112,384 shares of the biopharmaceutical company’s stock, valued at approximately $717,000. Allianz Asset Management GmbH owned about 0.21% of Emergent Biosolutions as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in the company. Vanguard Personalized Indexing Management LLC boosted its holdings in Emergent Biosolutions by 14.1% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 17,824 shares of the biopharmaceutical company’s stock valued at $114,000 after acquiring an additional 2,204 shares during the last quarter. PFG Investments LLC bought a new position in Emergent Biosolutions in the second quarter valued at about $73,000. Janney Montgomery Scott LLC bought a new position in Emergent Biosolutions in the second quarter valued at about $68,000. Public Employees Retirement System of Ohio lifted its stake in shares of Emergent Biosolutions by 135.9% in the 2nd quarter. Public Employees Retirement System of Ohio now owns 13,181 shares of the biopharmaceutical company’s stock valued at $84,000 after purchasing an additional 7,593 shares during the period. Finally, Kingstone Capital Partners Texas LLC acquired a new position in shares of Emergent Biosolutions in the 2nd quarter valued at $227,000. Institutional investors own 78.40% of the company’s stock.

Insider Activity

In other news, Director Donald W. Degolyer sold 7,844 shares of Emergent Biosolutions stock in a transaction dated Tuesday, August 12th. The stock was sold at an average price of $8.65, for a total transaction of $67,850.60. Following the transaction, the director owned 137,659 shares in the company, valued at $1,190,750.35. The trade was a 5.39% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Coleen Glessner sold 30,608 shares of Emergent Biosolutions stock in a transaction dated Tuesday, October 7th. The shares were sold at an average price of $10.00, for a total value of $306,080.00. Following the transaction, the executive vice president owned 144,319 shares in the company, valued at $1,443,190. This trade represents a 17.50% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 45,538 shares of company stock worth $436,783 in the last 90 days. Corporate insiders own 3.20% of the company’s stock.

Emergent Biosolutions Price Performance

Shares of EBS opened at $9.77 on Monday. The company has a current ratio of 5.66, a quick ratio of 3.00 and a debt-to-equity ratio of 1.25. Emergent Biosolutions Inc. has a 1 year low of $4.02 and a 1 year high of $12.73. The stock has a market cap of $520.96 million, a P/E ratio of 3.99 and a beta of 2.04. The stock’s 50-day moving average price is $8.78 and its two-hundred day moving average price is $7.18.

Emergent Biosolutions (NYSE:EBS) last issued its earnings results on Tuesday, January 9th. The biopharmaceutical company reported ($1.27) earnings per share (EPS) for the quarter. Emergent Biosolutions had a return on equity of 24.63% and a net margin of 16.38%.The company had revenue of $222.50 million for the quarter. Emergent Biosolutions has set its FY 2023 guidance at EPS. On average, equities analysts predict that Emergent Biosolutions Inc. will post -0.63 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the company. Wall Street Zen downgraded Emergent Biosolutions from a “buy” rating to a “hold” rating in a research note on Saturday, August 9th. Weiss Ratings restated a “sell (d)” rating on shares of Emergent Biosolutions in a report on Friday. Finally, HC Wainwright restated a “buy” rating and set a $15.00 target price on shares of Emergent Biosolutions in a report on Wednesday, September 3rd. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $13.50.

About Emergent Biosolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.